Literature DB >> 20736077

Early CMV viremia is associated with impaired viral control following nonmyeloablative hematopoietic cell transplantation with a total lymphoid irradiation and antithymocyte globulin preparative regimen.

Joanna M Schaenman1, Sumana Shashidhar, Chanu Rhee, Jonathan Wong, Shelly Navato, Ruby M Wong, Dora Y Ho, Sally Arai, Laura Johnston, Janice M Brown.   

Abstract

The reconstitution of immune function after hematopoietic cell transplant (HCT) plays an important role in the control of viral infections. Both donor and recipient cytomegalovirus (CMV) serostatus has been shown to contribute to effective immune function; however, the influence of a nonmyeloablative preparative (NMA) regimen using total lymphoid irradiation (TLI) and antithymocyte globulin (ATG) on antiviral immune reconstitution has not yet been described. In 117 recipients of NMA HCT patients following ATG and TLI, not unexpectedly, CMV viremia was seen in approximately 60% of the seropositive patients regardless of donor serostatus, and recipient seropositivity significantly increased the odds of CMV viremia after transplant in a multivariate analysis. The administration of ATG and TLI resulted in a strikingly earlier viremia in the posttransplant period when compared to the previously reported timing of viremia following myeloablative preparative regimens, especially for transplant recipients who were seropositive for CMV with seronegative donors. Furthermore, early viremia in the setting of a CMV naïve donor was associated with a delay in functional antiviral control. These observations demonstrate the dynamic nature of immunity in relation to CMV antigen exposure in the complex environment resulting from NMA conditions where both donor and residual recipient immune response affect viral control.
Copyright © 2011 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20736077      PMCID: PMC5508721          DOI: 10.1016/j.bbmt.2010.08.010

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


  24 in total

1.  Infectious complications following allogeneic HLA-identical sibling transplantation with antithymocyte globulin-based reduced intensity preparative regimen.

Authors:  M Mohty; W Jacot; C Faucher; J O Bay; C Zandotti; L Collet; B Choufi; K Bilger; O Tournilhac; N Vey; A M Stoppa; D Coso; J A Gastaut; P Viens; D Maraninchi; D Olive; D Blaise
Journal:  Leukemia       Date:  2003-11       Impact factor: 11.528

2.  High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution.

Authors:  Suparno Chakrabarti; Stephen Mackinnon; Raj Chopra; Panagiotis D Kottaridis; Karl Peggs; Peter O'Gorman; Ronjon Chakraverty; Timothy Marshall; Husam Osman; Premini Mahendra; Charles Craddock; Herman Waldmann; Geoff Hale; Christopher D Fegan; Kwee Yong; Anthony H Goldstone; David C Linch; Donald W Milligan
Journal:  Blood       Date:  2002-06-15       Impact factor: 22.113

3.  Direct visualization of cytomegalovirus-specific T-cell reconstitution after allogeneic stem cell transplantation.

Authors:  K Cwynarski; J Ainsworth; M Cobbold; S Wagner; P Mahendra; J Apperley; J Goldman; C Craddock; P A Moss
Journal:  Blood       Date:  2001-03-01       Impact factor: 22.113

4.  Protective conditioning for acute graft-versus-host disease.

Authors:  Robert Lowsky; Tsuyoshi Takahashi; Yin Ping Liu; Sussan Dejbakhsh-Jones; F Carl Grumet; Judith A Shizuru; Ginna G Laport; Keith E Stockerl-Goldstein; Laura J Johnston; Richard T Hoppe; Daniel A Bloch; Karl G Blume; Robert S Negrin; Samuel Strober
Journal:  N Engl J Med       Date:  2005-09-29       Impact factor: 91.245

5.  Immunological response to cytomegalovirus in congenitally infected neonates.

Authors:  J Hassan; S Dooley; W Hall
Journal:  Clin Exp Immunol       Date:  2007-03       Impact factor: 4.330

6.  Patterns of cytomegalovirus reactivation are associated with distinct evolutive profiles of immune reconstitution after allogeneic hematopoietic stem cell transplantation.

Authors:  Hélène Moins-Teisserenc; Marc Busson; Catherine Scieux; Véronique Bajzik; Jean-Michel Cayuela; Emmanuel Clave; Régis Peffault de Latour; Félix Agbalika; Patricia Ribaud; Marie Robin; Vanderson Rocha; Eliane Gluckman; Dominique Charron; Gérard Socié; Antoine Toubert
Journal:  J Infect Dis       Date:  2008-09-15       Impact factor: 5.226

Review 7.  Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies.

Authors:  Michael Boeckh; W Garrett Nichols; Genovefa Papanicolaou; Robert Rubin; John R Wingard; John Zaia
Journal:  Biol Blood Marrow Transplant       Date:  2003-09       Impact factor: 5.742

8.  Infectious complications associated with alemtuzumab use for allogeneic hematopoietic stem cell transplantation: comparison with anti-thymocyte globulin.

Authors:  S H Park; S-M Choi; D-G Lee; J-H Choi; J-H Yoo; S-H Kim; H-J Kim; S-G Cho; K-S Eom; J-W Lee; W-S Min; W-S Shin; C-C Kim
Journal:  Transpl Infect Dis       Date:  2009-08-24       Impact factor: 2.228

Review 9.  CMV-specific T cell therapy.

Authors:  Hermann Einsele; Markus Kapp; Götz Ulrich Grigoleit
Journal:  Blood Cells Mol Dis       Date:  2007-09-11       Impact factor: 3.039

10.  Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection.

Authors:  Daniele Lilleri; Chiara Fornara; Antonella Chiesa; Daniela Caldera; Emilio Paolo Alessandrino; Giuseppe Gerna
Journal:  Haematologica       Date:  2008-02       Impact factor: 9.941

View more
  4 in total

1.  Risks and benefits of sex-mismatched hematopoietic cell transplantation differ according to conditioning strategy.

Authors:  Hideki Nakasone; Mats Remberger; Lu Tian; Petter Brodin; Bita Sahaf; Fang Wu; Jonas Mattsson; Robert Lowsky; Robert Negrin; David B Miklos; Everett Meyer
Journal:  Haematologica       Date:  2015-08-06       Impact factor: 9.941

Review 2.  Cytomegalovirus pneumonia in hematopoietic stem cell recipients.

Authors:  Giovanna Travi; Steven A Pergam
Journal:  J Intensive Care Med       Date:  2013-02-06       Impact factor: 3.510

3.  Prophylactic rituximab after allogeneic transplantation decreases B-cell alloimmunity with low chronic GVHD incidence.

Authors:  Sally Arai; Bita Sahaf; Balasubramanian Narasimhan; George L Chen; Carol D Jones; Robert Lowsky; Judith A Shizuru; Laura J Johnston; Ginna G Laport; Wen-Kai Weng; Jonathan E Benjamin; Joanna Schaenman; Janice Brown; Jessica Ramirez; James L Zehnder; Robert S Negrin; David B Miklos
Journal:  Blood       Date:  2012-05-04       Impact factor: 22.113

4.  Antithymocyte globulin improves the survival of patients with myelodysplastic syndrome undergoing HLA-matched unrelated donor and haplo-identical donor transplants.

Authors:  Hong Wang; Hong Liu; Jin-Yi Zhou; Tong-Tong Zhang; Song Jin; Xiang Zhang; Su-Ning Chen; Wei-Yang Li; Yang Xu; Miao Miao; De-Pei Wu
Journal:  Sci Rep       Date:  2017-03-06       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.